A successful case of assisted pregnancy after highly effective progestogen treatment for endometrial carcinoma patient with KRAS gene mutation
10.3760/cma.j.cn101441-20221109-00492
- VernacularTitle:KRAS基因突变子宫内膜癌患者高效孕激素治疗后成功助孕1例病案报道
- Author:
Hongxia ZHANG
1
;
Huajun LI
1
;
Rui YANG
1
;
Hongbin CHI
1
;
Ping LIU
1
;
Rong LI
1
;
Jie QIAO
1
Author Information
1. 北京大学第三医院妇产科 国家妇产疾病临床医学研究中心，北京 100191
- Publication Type:Journal Article
- Keywords:
Fertilization in vitro;
Embryo transfer;
Endometrial carcinoma;
KRAS gene mutation;
Fertility-preserving therapy
- From:
Chinese Journal of Reproduction and Contraception
2023;43(12):1268-1271
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the curative effect of fertility-preserving therapy for endometrial carcinoma patient with KRAS gene mutation and the choice of pregnancy-assisting strategy. Methods:We reported the fertility-preserving treatment and pregnancy-assisted process of a case of endometrial carcinoma patient with KRAS gene mutation and analyzed the related literatures. Results:After 20 months of treatment with highly effective progestogen and intrauterine levonorgestrel-releasing intrauterine system (LNG-IUS), the patient achieved complete remission. Antagonist plus letrozole was used to induce ovulation. After LNG-IUS was taken out, the pregnancy from blastocyst transfer was achieved after downregulation and artificial cycle, and a live baby girl was born at term.Conclusion:Endometrial carcinoma patient with KRAS gene mutation can achieve complete remission and fertility after combined treatment, but the treatment period is long, therefore, it is necessary to closely monitor changes of the disease.
